Document type: | Patente |
Inventor(s): | José Agustín Pablo Quincoces Suárez; Klaus Peseke; Marcus Kordian; João Ernesto de Carvalho; Luciana Konecny Kohn; Maria Aparecida Antônio; Heloiza Brunhari |
Applicant: | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) |
Deposit date: | November 2003, 08 |
INPI register: | |
IPC: | C07C 49/248 C07C 49/255 C07C 67/08 C07C 45/71 C07C 45/74 |
This patent of invention reports the method for the preparation of 1,5-bis(4-hydroxy-3-methoxyphenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties: the sample denominated 37 compound was obtained with high yield and purity with ultrasonic technique presenting cytostatic activity (growth inhibition) in the concentrations evaluated and cytotoxic activity (cellular death) from the concentration of 0,25 mg/mL against nine different types of human cancer cell lines. This compound has a LD50, equals to 8,54 g/Kg. That means this product can be considered itself as practically nontoxic. Doxorubicin, anticarcinogen medicine used as reference in all these tests, is a product extremely toxic (LD50 of 20 mg/Kg) and it does not inhibit the growth of Mama NCI-ADR cell line (the one that expresses the phenotype of resistance against multiple drugs), therefore our product presented a strong cytostatic activity. Other derivatives also presented a strong cytostatic activity, specially the one denominated EHB1 compound.
Grantee: | José Agustín Pablo Quincoces Suárez |
Principal Investigator: | José Agustín Pablo Quincoces Suárez |
Institution: | Universidade Bandeirantes (UNIBAN). Pró-Reitoria Acadêmica |
Support Opportunities: | Scholarships abroad - Research |
Grantee: | José Agustín Pablo Quincoces Suárez |
Principal Investigator: | José Agustín Pablo Quincoces Suárez |
Institution: | Universidade Bandeirantes (UNIBAN). Pró-Reitoria Acadêmica |
Support Opportunities: | Research Grants - Support for Intellectual Property Rights and Licensing (PAPI/Nuplitec) |